AG
PTCT icon

Algert Global’s PTC Therapeutics PTCT Stock Holding History

Algert Global’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28,309
Closed -$1.05M – 1297
2024
Q3 		$1.05M Hold
28,309
– – 0.03% 740
2024
Q2 		$866K Buy
+28,309
New +$917K 0.03% 720
2024
Q1 		– Sell
-36,000
Closed -$992K – 1228
2023
Q4 		$992K Buy
+36,000
New +$823K 0.04% 622

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Algert Global's PTCT Position: Q4 2024 in Review

Algert Global sold out of PTC Therapeutics (PTCT) in Q4 2024, closing a stake of 28,309 shares — an estimated $1.05M sold.

Algert Global first reported a position in PTCT in Q4 2023 and held it in 3 quarters. The position peaked at $1.05M in Q3 2024. 239 funds tracked by Wall St. Rank hold PTCT as of Q4 2024.

  • Algert Global reported no remaining PTC Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Algert Global sold 28,309 PTC Therapeutics shares in Q4 2024, an estimated $1.05M.
  • Algert Global first reported a position in PTC Therapeutics in Q4 2023 and held it in 3 quarters.
  • Algert Global's PTC Therapeutics position peaked at $1.05M in Q3 2024.
  • 239 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2024.

Based on Algert Global's 13F filing for Q4 2024, filed 14 Feb 2025.